Bridgebio Pharma Inc Revenue Growth Rates (BBIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bridgebio Pharma Inc   (NASDAQ: BBIO)
 

BBIO's Revenue Growth by Quarter and Year

Bridgebio Pharma Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BBIO/growth
https://api.csimarket.com/api/v1/companies/BBIO/fundamentals
https://api.csimarket.com/api/v1/companies/BBIO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BBIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 353.17
2nd Quarter June 243.68
1st Quarter March 194.52
FY 791.37

BBIOs Annual Revenue
Bridgebio Pharma Inc 's Revenue in the fiscal year 2025 $ 502.08 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2024 $ 221.90 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2023 $ 9.30 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2022 $ 77.65 millions
Bridgebio Pharma Inc 's Revenue in the fiscal year 2021 $ 69.72 millions




BBIO Revenue third quarter 2026 Y/Y Growth Comment
Bridgebio Pharma Inc reported Revenue surge of 192.6% year on year in the third quarter 2026, to $ 353.17 millions, this is lower than Bridgebio Pharma Inc 's recent average Revenue surge of 1593.07%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Revenue growth. While Bridgebio Pharma Inc ' s Revenue doubling of 192.6% ranks overall at the positon no. 220 in the third quarter 2026.


BBIO Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 192.6 %
2nd Quarter June 120.39 %
1st Quarter March 66.78 %
FY   -

Financial Statements
Bridgebio Pharma Inc 's third quarter 2026 Revenue $ 353.17 millions BBIO's Income Statement
Bridgebio Pharma Inc 's third quarter 2025 Revenue $ 120.70 millions Quarterly BBIO's Income Statement


BBIO Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 44.93 %
2nd Quarter June 25.27 %
1st Quarter March 26.16 %
FY (Year on Year)   -


Back to BBIO Growth rate Comparisons >> Back to BBIO Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #62
Overall #220

Revenue Y/Y Growth Statistics
High Average Low
11461.88 % 1593.07 % -99.12 %
(Jun 30 2024)   (Jun 30 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #62
Overall #220
Revenue Y/Y Growth Statistics
High Average Low
11461.88 % 1593.07 % -99.12 %
(Jun 30 2024)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bridgebio Pharma Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
11998.57 % 1223.44 % -100 %
(Mar 31 2024)  


BBIO's III. Quarter Q/Q Revenue Comment
Bridgebio Pharma Inc achieved in the III. Quarter 2026 below company average Revenue jump of 44.93% quarter on quarter, to $ 353.17 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 9.16% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Bridgebio Pharma Inc 's Revenue growth quarter on quarter, overall rank is 425.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #94
Overall #425
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #94
Overall #425
Revenue Q/Q Growth Statistics
High Average Low
11998.57 % 1223.44 % -100 %
(Mar 31 2024)  


BBIO's III. Quarter Q/Q Revenue Comment
Bridgebio Pharma Inc achieved in the III. Quarter 2026 below company average Revenue jump of 44.93% quarter on quarter, to $ 353.17 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 9.16% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Bridgebio Pharma Inc 's Revenue growth quarter on quarter, overall rank is 425.


Bridgebio Pharma Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 945.54
Y / Y Revenue Growth (TTM) 167.27 %
Year on Year Revenue Growth Overall Ranking # 1648
Seqeuential Revenue Change (TTM) 32.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 194


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Bridgebio Pharma Inc 's cumulative twelve months Revenue were $ 946 millions, company would post below average annual Revenue growth of 32.6% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Bridgebio Pharma Inc 's Revenue growth from the 243.68% growth in Jun 30 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1648, from total ranking in previous quarter at 2857.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 264
Overall # 1648

Revenue TTM Y/Y Growth Statistics
High Average Low
3761.22 %
 529.39 %
-93.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 52
S&P 500 # 194
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Bridgebio Pharma Inc 's cumulative twelve months Revenue were $ 946 millions, company would post below average annual Revenue growth of -93.74% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Bridgebio Pharma Inc 's Revenue growth from the 243.68% growth in Jun 30 2026.

In the Healthcare sector 263 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1648, from total ranking in previous quarter at 2857.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 264
Overall # 1648

Revenue TTM Y/Y Growth Statistics
High Average Low
3761.22 %
529.39 %
-93.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 52
S&P 500 # 194




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BBIO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions


About Bridgebio Pharma Inc Revenue Growth Rates (BBIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bridgebio Pharma Inc (CIK 1743881).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001743881-26-000034
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bridgebio Pharma Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.